Answers are grounded in this paper and cite their sources.
There is a pressing need for the development of advanced heart failure therapeutics. Current state-of-the-art is protection from neurohumoral overstimulation, which fails to address the underlying cause of heart failure, namely loss of cardiomyocytes. Implantation of stem cell-derived cardiomyocytes via tissue-engineered myocardium is being advanced to realize the remuscularization of the failing heart. Here, we discuss pharmacological challenges pertaining to the clinical translation of tissue-engineered heart repair with a focus on engineered heart muscle (EHM).
No takes yet. Share an insight, caveat, or question.
Fujita et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: